Market Closed -
Nasdaq
04:00:00 2024-05-09 pm EDT
|
5-day change
|
1st Jan Change
|
3.27
USD
|
+5.48%
|
|
+5.14%
|
+41.56%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
48.46
|
176.7
|
128.5
|
72.39
|
254.1
|
347.5
|
-
|
-
|
Enterprise Value (EV)
1 |
64.53
|
171.2
|
50.96
|
27.14
|
254.1
|
219
|
205.4
|
347.5
|
P/E ratio
|
-
|
-1.09
x
|
51.6
x
|
-10.3
x
|
-45.4
x
|
-331
x
|
-67.1
x
|
-38.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
3.52
x
|
-
|
25.4
x
|
12.6
x
|
27.8
x
|
332
x
|
EV / Revenue
|
-
|
-
|
1.4
x
|
-
|
25.4
x
|
7.96
x
|
16.4
x
|
332
x
|
EV / EBITDA
|
-
|
-4,758,884
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-17.2
x
|
-8.96
x
|
-13.3
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-5.8%
|
-11.2%
|
-7.51%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
19,592
|
67,495
|
108,655
|
116,734
|
139,996
|
140,024
|
-
|
-
|
Reference price
2 |
2.474
|
2.618
|
1.183
|
0.6201
|
1.815
|
2.481
|
2.481
|
2.481
|
Announcement Date
|
6/15/20
|
3/31/21
|
3/31/22
|
3/28/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
36.46
|
-
|
10
|
27.5
|
12.5
|
1.045
|
EBITDA
|
-
|
-35.97
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-39.52
|
-37.57
|
-20.94
|
-43.57
|
-28.42
|
-38.03
|
-43.02
|
-44.55
|
Operating Margin
|
-
|
-
|
-57.42%
|
-
|
-284.16%
|
-138.29%
|
-344.2%
|
-4,263.35%
|
Earnings before Tax (EBT)
1 |
-41.12
|
-166.4
|
14.24
|
-36.09
|
-30
|
-29.48
|
-33.17
|
-44.55
|
Net income
1 |
-34.84
|
-163.6
|
12.72
|
-34.2
|
-29.47
|
-8.265
|
-28.71
|
-44.55
|
Net margin
|
-
|
-
|
34.9%
|
-
|
-294.66%
|
-30.06%
|
-229.7%
|
-4,263.35%
|
EPS
2 |
-
|
-2.410
|
0.0229
|
-0.0600
|
-0.0400
|
-0.007500
|
-0.0370
|
-0.0640
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-
|
-12.71
|
-22.92
|
-26.11
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-46.21%
|
-183.36%
|
-2,498.33%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/15/20
|
3/31/21
|
3/31/22
|
3/28/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019 S2
|
2020 S1
|
2020 S2
|
2021 S1
|
2021 Q3
|
2021 Q4
|
2021 S2
|
2022 Q2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
2024 S1
|
2024 S2
|
2025 S1
|
2025 S2
|
---|
Net sales
1 |
-
|
-
|
-
|
36.46
|
-
|
-
|
-
|
-
|
-
|
-
|
7.128
|
2.872
|
12.5
|
15
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-21.14
|
-16.69
|
-20.88
|
-0.204
|
-10.37
|
-10.37
|
-20.73
|
-
|
-21.81
|
-21.76
|
-9.909
|
-18.51
|
-18.6
|
-19.43
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-0.56%
|
-
|
-
|
-
|
-
|
-
|
-
|
-139.02%
|
-644.39%
|
-148.8%
|
-129.54%
|
-
|
-
|
Earnings before Tax (EBT)
|
-22.44
|
-126.1
|
-40.35
|
10.9
|
-
|
-
|
3.337
|
-
|
-19.89
|
-16.2
|
-11.94
|
-18.06
|
-14.6
|
-14.88
|
-15
|
-15
|
Net income
|
-18.62
|
-124.6
|
-39.01
|
12.09
|
-
|
-
|
0.637
|
-
|
-19.16
|
-15.04
|
-11.03
|
-18.44
|
-5.05
|
-3.24
|
-15
|
-15
|
Net margin
|
-
|
-
|
-
|
33.15%
|
-
|
-
|
-
|
-
|
-
|
-
|
-154.74%
|
-641.92%
|
-40.4%
|
-21.6%
|
-
|
-
|
EPS
|
-
|
-
|
-0.3500
|
0.0223
|
-0.1700
|
-0.1700
|
0.000620
|
-
|
-0.0300
|
-0.0300
|
-0.0200
|
-0.0200
|
-0.008500
|
-0.003500
|
-0.0200
|
-0.0200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/15/20
|
9/29/20
|
3/31/21
|
11/2/21
|
3/31/22
|
3/31/22
|
3/31/22
|
11/2/22
|
11/2/22
|
3/28/23
|
9/7/23
|
3/27/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
16.1
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
5.53
|
77.5
|
45.2
|
-
|
129
|
142
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-
|
-12.7
|
-22.9
|
-26.1
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.02
|
0.02
|
0.54
|
0.01
|
-
|
1
|
3
|
11
|
Capex / Sales
|
-
|
-
|
1.47%
|
-
|
-
|
3.64%
|
24%
|
1,052.63%
|
Announcement Date
|
6/15/20
|
3/31/21
|
3/31/22
|
3/28/23
|
3/27/24
|
-
|
-
|
-
|
Last Close Price
2.481
GBP Average target price
4.977
GBP Spread / Average Target +100.58% Consensus |
1st Jan change
|
Capi.
|
---|
| +34.20% | 434M | | +2.93% | 108B | | -2.56% | 23.46B | | -14.60% | 21.72B | | -7.05% | 18.64B | | -38.55% | 17.45B | | -8.83% | 17.19B | | +5.51% | 13.99B | | +37.49% | 12.53B | | +329.39% | 8.81B |
Bio Therapeutic Drugs
|